SV

Street Verdict

Analyst Scorecard

PANACEABIO · NSE

Panacea Biotec Limited

₹335.95

-4.79% (-₹16.9)

Prev. close

₹352.85

Volume

1,33,412

Delivery %

52.6%

As of

20 Nov 2026

Price history

₹335.95-₹69.9 (-17.22%) · 3M
18 Aug 2026 → 20 Nov 2026
32034036038040018 Aug09 Sept06 Oct29 Oct20 Nov
Daily closes · updates after each session

Analyst sentiment

No analyst stances in this range

0 analyst stances · last 90 days · one per analyst

Try a wider range.

Explore by date range →

Analyst opinions

CallAnalystInstrumentVerdictActions

Fundamentals

About Panacea Biotec Limited

Panacea Biotec Limited, a biotechnology company, engages in the research, development, manufacture, and marketing of vaccines, pharmaceutical formulations, nutraceuticals, and food and nutrition products in India and internationally. The company operates through Vaccines and Pharmaceutical Formulations & Nutrition segments. Its product portfolio includes prescription products in various therapeutic areas, such as diabetes, gastro-intestinal care, nephrology, oncology, orthopedics, pain management, and fever; cold and cough; and betacoronavirus, SARS-CoV-2, typhoid conjugate, pneumococcal conjugate, tetravalent dengue, and Mpox, etc. The company also offers health supplement products; and nutrition products under the ChilRun full, ChilRun 7+, and ChillRun No Sucrose brands. In addition, it engages in the real estate business. It exports its products to approximately 50 countries. It has collaboration agreements with the Russian Direct Investment Fund for producing Covid-19 vaccine, and Sputnik-V; and the Indian Council of Medical Research for clinical trials of DengiAll vaccine. Panacea Biotec Limited was incorporated in 1984 and is based in New Delhi, India.

Details

Sector

Healthcare

Industry

Biotechnology

CEO

Dr. Rajesh Jain Ph.D.

Headquarters

New Delhi

Employees

2,102

Key stats

Market cap

₹2,107.06 Cr

Dividend yield

0.00%

EPS (TTM)

₹-1.16

Beta (1Y · daily vs NIFTY 50)

1.08

Beta (5Y · monthly vs NIFTY 50)

1.25

Shares float

1.66 Cr

EPS · quarter ended Jun 2026

₹0.38

Financial Performance

01 · Financials

-1000 Cr0 Cr1000 Cr2000 Cr₹-100%0%100%200%FY22FY23FY24FY25FY26
RevenueNet incomeEBITDANet income ÷ revenue

02 · Earnings Per Share (EPS)

-1000100200₹FY21FY22FY23FY24FY25FY26

04 · Operating Efficiency (Growth Rates)

Balance-sheet-based

-40%-20%0%20%40%FY21FY22FY23FY24FY25FY26
SalesFixed assetsTrade receivablesInventory

05 · Capital Structure & Asset Utilization

0 Cr500 Cr1000 Cr1500 Cr2000 Cr₹0×0.2×0.4×0.6×FY21FY22FY23FY24FY25FY26
Total assetsTotal debtDebt / equityAsset turnover

Debt/equity omitted where reported equity was zero or negative. Asset turnover needs a prior year of assets — omitted for the earliest available year.

06 · Asset Base Composition

0 Cr500 Cr1000 Cr1500 Cr2000 Cr₹FY21FY22FY23FY24FY25FY26
Fixed assetsCurrent assetsOther assets

07 · Debt Level & Coverage

-500 Cr0 Cr500 Cr1000 Cr₹FY21FY22FY23FY24FY25FY26
DebtFree cash flowCash & equivalents

08 · Profit & Loss

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹624.81 Cr₹661.23 Cr₹459.95 Cr₹559.17 Cr₹492.60 Cr₹639.77 Cr
EBITDA
₹86.62 Cr₹1,673.32 Cr₹56.36 Cr₹41.77 Cr₹30.74 Cr₹31.74 Cr
₹-147.65 Cr₹1,077.91 Cr₹-33.24 Cr₹-1.17 Cr₹-8.37 Cr₹-5.37 Cr
Diluted EPS
₹-24.11₹175.98₹-5.43₹-0.19₹-1.37₹-0.88

Depreciation & amortisation has filed figures for only some of the years shown — the missing years are left blank rather than estimated.

09 · Balance Sheet

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹1,177.53 Cr₹1,758.87 Cr₹1,271.16 Cr₹1,240.68 Cr₹1,289.75 Cr₹1,262.17 Cr
₹819.53 Cr₹34.16 Cr₹20.22 Cr₹15.00 Cr₹15.00 Cr₹15.00 Cr
Stockholders' equity
₹-228.69 Cr₹876.64 Cr₹843.61 Cr₹842.05 Cr₹834.79 Cr₹834.84 Cr

Trade receivables, CWIP, Others, Long-term debt, Current (short-term) debt have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.

10 · Cash Flow Statement

Annual

Line itemFY21FY22FY23FY24FY25FY26
₹106.76 Cr₹-108.43 Cr₹-423.46 Cr₹3.47 Cr₹-27.37 Cr₹16.68 Cr
Investing cash flow
₹-47.68 Cr₹1,282.57 Cr₹430.33 Cr₹6.66 Cr₹64.98 Cr₹-40.49 Cr
₹-47.11 Cr₹-1,175.85 Cr₹-18.38 Cr₹-2.81 Cr₹-2.66 Cr₹-1.05 Cr
Capital expenditure
—₹-17.51 Cr₹-40.95 Cr₹-82.88 Cr₹-50.31 Cr₹-54.09 Cr
End cash position
₹52.08 Cr₹50.35 Cr₹39.85 Cr₹47.17 Cr₹82.13 Cr₹57.31 Cr

Depreciation & amortization, Debt issued, Debt repaid, Capital expenditure have filed figures for only some of the years shown — the missing years are left blank rather than estimated.

Annual only — the data source has no quarterly cash-flow-statement coverage.

11 · Shareholding Pattern

NSE, quarterly

Line itemSep 21–Mar 24(11Q)Jun 24Sep 24Dec 24Mar 25–Jun 26(6Q)
Promoter73.59%73.46%72.87%72.49%72.48%
Public26.41%26.54%27.13%27.51%27.52%
Employee trusts0.00%0.00%0.00%0.00%0.00%

Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.

12 · Peer Comparison

Healthcare

Company
Sun Pharmaceutical Industries Limited₹4.25 L Cr₹1,769.938.85.0913.7%0.06+11.9%+3.7%
Divi's Laboratories Limited₹2.66 L Cr₹10,037.590.815.8515.3%0.00+12.3%+47.5%
Torrent Pharmaceuticals Limited₹1.79 L Cr₹4,738.579.421.3125.8%1.79+21.5%+32.5%
Laurus Labs Limited₹1.27 L Cr₹2,34894.823.9416.8%0.48+22.0%+146.2%
Apollo Hospitals Enterprise Limited₹1.23 L Cr₹8,599.558.812.9520.5%0.90+15.7%+10.1%
Zydus Lifesciences Limited₹1.19 L Cr₹1,188.126.74.4018.6%0.46+18.4%+22.3%
Lenskart Solutions Limited₹1.16 L Cr₹689.7181.413.305.6%0.35+35.4%—
Dr. Reddy's Laboratories Limited₹1.14 L Cr₹1,37440.63.0211.4%0.21+3.2%+14.5%
Cipla Limited₹1.13 L Cr₹1,40238.93.2711.3%0.02+2.1%-6.7%
Mankind Pharma Limited₹1.03 L Cr₹2,47545.96.3111.7%0.39+17.0%+3.1%
Aurobindo Pharma Limited₹98,101.93 Cr₹1,70526.62.599.2%0.21+6.4%+48.4%
Panacea Biotec Limited₹2,045.64 Cr₹344.8—2.45-0.6%0.02+23.8%-20.2%

Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.

PANACEABIO

Panacea Biotec's (NSE:PANACEABIO) Earnings Are Weaker Than They Seem

Simply Wall St · 17 hours ago

PANACEABIO

Pharma sector stocks today, November 18: Indoco Remedies jumps 11.17%, Glenmark Pharma gains 1.35%; Panacea Biotec down 1.36%

Business Upturn · 5 days ago